Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Giant-Cell Arteritis Market Growth From $1.17 Billion In 2026 To $1.39 Billion By 2030 At A CAGR Of 4.3%

The global market for giant-cell arteritis experienced consistent expansion recently, projected to advance from a value of $1.12 billion in 2025 to $1.18 billion in 2026, reflecting a compound annual growth rate of 4.9%. This upward trajectory during the preceding period was fueled by several key factors, including a growing elderly demographic, continued reliance on corticosteroid treatments, enhancements in the quality of rheumatological care, the proliferation of hospital-based treatment options, and heightened public and medical awareness of the condition.

The market for giant-cell arteritis is projected to experience consistent expansion over the upcoming years, reaching an estimated $1.39 billion by 2030 with a compound annual growth rate of 4.3%. This anticipated growth is fueled by several key factors including the introduction of new biologic drugs, advancements in immunological research, enhancements in diagnostic procedures, the development of individualized treatment approaches for vasculitis, and the proliferation of specialized treatment centers. During this forecast period, prominent trends will involve a greater acceptance of biologic treatments, an intensified emphasis on prompt and precise diagnosis, wider utilization of therapies that minimize corticosteroid reliance, more effective long-term patient monitoring, and heightened public awareness regarding the prevention of vision impairment.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

Giant-Cell Arteritis Market Opportunity Drivers: What Is Creating New Revenue Potential?

The expanding focus on individualized medical approaches is anticipated to be a significant catalyst for the expansion of the giant-cell arteritis market. This trend toward personalized medicine, which centers on customizing treatments to an individual’s unique genetic makeup, lifestyle, and environmental influences, is gaining momentum thanks to breakthroughs in genomics, biotechnology, and data analysis. These advancements facilitate the development of therapies precisely targeted to a patient’s specific needs, thereby enhancing treatment effectiveness and minimizing unwanted side effects. In the context of GCA, personalized medicine offers the potential for highly specific interventions based on factors like a patient’s genetic susceptibility, immune system characteristics, and the particular way their disease presents. Indicating the widespread adoption of this methodology, the Personalized Medicine Coalition noted in February 2024 that personalized medicines represented more than a third of all new drug approvals by the FDA in 2023, marking the fourth year in a row this trend has held true. That same year saw 16 new personalized treatments greenlit by the FDA, predominantly for uncommon conditions, a notable increase from the 6 such approvals in 2022, with these 2023 approvals also including seven cancer drugs and three treatments for a range of other ailments. Consequently, the increasing prominence of tailored medical treatments is a key driver for the growth observed in the giant-cell arteritis market.

Giant-Cell Arteritis Market Segment Analysis And Revenue Opportunities

The giant-cell arteritis market covered in this report is segmented –

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

Giant-Cell Arteritis Market Innovation Trends Driving Future Development

The landscape of giant-cell arteritis treatment is being enhanced by leading pharmaceutical firms introducing novel therapeutics, including biosimilars, aimed at broadening therapeutic choices and fulfilling persistent patient requirements. A biosimilar signifies a biological medicinal product that closely mirrors an existing, authorized biologic formulation, exhibiting no significant clinical disparities in its safety profile, purity, or efficacy. By way of illustration, Fresenius SE & Co. KGaA, a health sector entity headquartered in Germany, introduced Tocilizumab-aazg in the United States during April 2024, offering a new treatment avenue for chronic autoimmune conditions. This particular biosimilar has received regulatory clearance for indications encompassing rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. The validation for its utilization stemmed from findings derived from a randomized, double-blind investigation conducted in phase 1, which involved a single dose administration and parallel group design, evaluating its pharmacokinetic properties, safety observations, and immunogenic response against both United States and European reference tocilizumab products across three distinct patient cohorts.

Giant-Cell Arteritis Market Leading Players Shaping Industry Direction

Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol-Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

Access The Complete Giant-Cell Arteritis Market Report:

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Giant-Cell Arteritis Market Regional Analysis And Leading Geography

North Americawas the largest region in the giant-cell arteritis market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model